Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
TE Stinchcombe, MA Socinski - The Oncologist, 2008 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the data on the patient populations enrolled and the efficacy of erlotinib and gefitinib in the …
the data on the patient populations enrolled and the efficacy of erlotinib and gefitinib in the …
Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?
TE Stinchcombe, MA Socinski - The Oncologist, 2008 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Learning Objectives</jats: title><
jats: p> After completing this course, the reader will be able to: Discuss the data on the …
jats: p> After completing this course, the reader will be able to: Discuss the data on the …
Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?
TE STINCHCOMBE, MA SOCINKSI - Oncologist, 2008 - search.ebscohost.com
There has been intense investigation into the epidermal growth factor receptor (EGFR) as a
therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there …
therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there …
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
TE Stinchcombe, MA Socinski - The oncologist, 2008 - pubmed.ncbi.nlm.nih.gov
There has been intense investigation into the epidermal growth factor receptor (EGFR) as a
therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there …
therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there …
[PDF][PDF] Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?
TE STINCHCOMBE, MA SOCINSKI - The Oncologist, 2008 - Citeseer
There has been intense investigation into the epidermal growth factor receptor (EGFR) as a
therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there …
therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there …
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
TE Stinchcombe, MA Socinski - The Oncologist, 2008 - europepmc.org
There has been intense investigation into the epidermal growth factor receptor (EGFR) as a
therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there …
therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there …
[PDF][PDF] Gefitinib in Advanced Non‐Small Cell Lung Cancer: Does It Deserve a Second Chance?
TE Stinchcombe, MA Socinski - The Oncologist, 2008 - Wiley Online Library
There has been intense investigation into the epidermal growth factor receptor (EGFR) as a
therapeutic target in the treatment of non‐small cell lung cancer (NSCLC). Currently there …
therapeutic target in the treatment of non‐small cell lung cancer (NSCLC). Currently there …
[PDF][PDF] Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?
TE STINCHCOMBE, MA SOCINSKI - Citeseer
There has been intense investigation into the epidermal growth factor receptor (EGFR) as a
therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there …
therapeutic target in the treatment of non-small cell lung cancer (NSCLC). Currently there …